DNA repair pathways in drug resistance in melanoma

Anti-Cancer Drugs

Volumn 15, Issue 5, 2004, Pages 421-426

  Bradbury, Penny A ^a   Middleton, Mark R ^a,b  

^a CHURCHILL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

DNA repair pathways; Drug resistance; Melanoma

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; APOPTOTIC PROTEASE ACTIVATING FACTOR 1; CISPLATIN; DACARBAZINE; DOUBLE STRANDED DNA; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE;

APOPTOSIS; CANCER CHEMOTHERAPY; CELL DAMAGE; CLINICAL TRIAL; DNA METHYLATION; DNA REPAIR; DNA STRAND BREAKAGE; EXCISION REPAIR; HUMAN; MELANOMA; METASTASIS; MISMATCH REPAIR; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW;

ANTINEOPLASTIC AGENTS; APOPTOSIS; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; HUMANS; MELANOMA; NEOPLASM METASTASIS; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE;

EID: 2942547591     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cad.0000127665.74096.93     Document Type: Review

References (58)

1. Schadendorf D, Worm M, Algermissen B, Kohlmus CM, Czarnetzki BM. Chemosensitivity testing of human malignant melanoma. A retrospective analysis of clinical response and in vitro drug sensitivity. Cancer 1994; 73:103-108.
2. DeVita Jr VT, Hellman S, Rosenberg SA (editors). Cancer: Principles and Practice of Oncology, 6th edn. Philadelphia, PA: Lippincott Williams & Wilkins; 2001, pp. 2051-2061.
3. Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, Panageas KS, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999; 17:2745-2751.
4. Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000; 18:158-166.
5. Jacquillat C, Khayat D, Banzet P, Weil M, Fumoleau P, Avril M, et al. Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastasis. Cancer 1990; 66:1873-1878.
6. Evans LM, Casper ES, Rosenbluth R. Phase II trial of carboplatin in advanced malignant melanoma. Cancer Treat Rep 1987; 71:171-172.
7. Glover D, Glick JH, Weiler C, Fox K, Guerry D. WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma. J Clin Oncol 1987; 5:574-578.
8. Quagliana JM, Stephens RL, Baker LH, Costanzi JJ. Vindesine in patients with metastatic malignant melanoma: a Southwest Oncology Group study. J Clin Oncol 1984; 2:316-319.
9. Bedikian AY, Weiss GR, Legha SS, Burris 3rd HA, Eckardt JR, Jenkins J, et al. Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy. J Clin Oncol 1995; 13:2895-2899.
10. Middleton MR, Lorigan P, Owen J, Ashcroft L, Lee SM, Harper P, et al. A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma. Br J Cancer 2000; 82:1158-1162.
11. Keilholz U, Conradt C, Legha SS, Khayat D, Scheibenbogen C, Thatcher N, et al. Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. J Clin Oncol 1998; 16: 2921-2929.
12. Atkins MB, Gollob JA, Sosman JA, McDermott DF, Tutin L, Sorokin P, et al. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma. Clin Cancer Res 2002; 8:3075-3081.
13. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, et al. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J Clin Oncol 1999; 17:968-975.
14. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002; 52:23-47.
15. Stevens MF, Hickman JA, Langdon SP, Chubb D, Vickers L, Stone R, et al. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3- methylimidazo[5,1-d]-1,2,3,5-tetra-4(3H)-one (CCRG 81045; M&B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res 1987; 47:5846-5852.
16. Saffhill RMG, O'Connor PJ. Mechanisms of carcinogenesis induced by alkylating agents. Biochim Biophys Acta 1985; 823:111-145.
17. Humbert O, Fiumicino S, Aquilina G, Branch P, Oda S, Zijno A, et al. Mismatch repair and differential sensitivity of mouse and human cells to methylating agents. Carcinogenesis 1999; 20:205-214.
18. 6-alkylguanine-DNA alkyltransferase. Prog Nucleic Acid Res Mol Biol 1995; 51:167-223.
19. Ayi TC, Loh KC, Ali RB, Li BF. Intracellular localization of human DNA repair enzyme methylguanine-DNA methyltransferase by antibodies and its importance. Cancer Res 1992; 52:6423-6430.
20. 6-methylguanine-DNA methyltransferase activity in human tumors. Carcinogenesis 1992; 13:1503-1507.
21. 6-alkylguanine-DNA alkyltransferase levels: studies with blasts of leukaemic patients. Ann Oncol 1995; 6:389-393.
22. 6-methylguanine in DNA to inactivation by alkylating agents including chloroethylnitrosoureas. Cancer Res 1984; 44:2467-2474.
23. 6-alkylguanine- DNA alkyltransferase to the anti-tumor agent 1-(4-amino-2-methyl-5-pyrimidinyl) methyl-3-(2-chloroethyl)-3-nitrosourea. Carcinogenesis 1989; 10:351-356.
24. 6-methylguanine-DNA methyltransferase activity and sensitivity of human tumor cell lines to bischloroethylnitrosourea. Clin Med Sci J 1992; 7:187-190.
25. 6-benzylguanine analogues on sensitivity of human tumor cells to the cytotoxic effects of alkylating agents. Cancer Res 1991; 51:3367-3372.
26. 6-methylguanine-DNA methyltransferase levels and clinical response induced by chloroethylnitrosourea therapy in glioma patients. Can J Neurol Sci 1999; 26:104-109.
27. 6-methylguanine-DNA methyltransferase in melanoma tumors in patients treated with dacarbazine-based chemotherapy. Melanoma Res 2002; 12:335-342.
28. 6-methylguanine-DNA methyltransferase in pretreatment tumor biopsies as a predictor of response to temozolomide in melanoma. Br J Cancer 1998; 78:1199-2202.
29. Smith DC, Gerson SL, Liu L, Donnelly S, Day R, Trump DL, et al. Carmustine and streptozocin in refractory melanoma: an attempt at modulation of O-alkylguanine-DNA-alkyltransferase. Clin Cancer Res 1996; 2:1129-1134.
30. Lee SM, Margison GP, Woodcock AA, Thatcher N. Sequential administration of varying doses of dacarbazine and fotemustine in advanced malignant melanoma. Br J Cancer 1993; 67:1356-1360.
31. 6-alkylguanine-DNA alkyltransferase depletion and regeneration in human peripheral lymphocytes following dacarbazine and fotemustine. Cancer Res 1991; 51:619-623.
32. 6-alkyl guanine-DNA transferase in blood lymphocytes and in tumors. Ann Oncol 1999; 10:831-838.
33. 6-methylguanine formation, repair protein depletion and clinical outcome with a 4 hr schedule of temozolomide in the treatment of advanced melanoma: results of a phase II study. Int J Cancer 2000; 88:469-473.
34. 6-benzylguanine followed by carmustine in patients with advanced cancer. Clin Cancer Res 2000; 6:3025-3031.
35. Evans AR, Limp-Foster M, Kelley MR. Going APE over ref-1. Mutat Res 2000; 461:83-108.
36. Prasad R, Lavrik OI, Kim SJ, Kedar P, Yang XP, Vande Berg BJ, et al. DNA polymerase beta-mediated long patch base excision repair. Poly(ADP-ribose) polymerase-1 stimulates strand displacement DNA synthesis. J Biol Chem 2001; 276:32411-32414.
37. Wang ZQ, Auer B, Stingl L, Berghammer H, Haidacher D, Schweiger M, et al. Mice lacking ADPRT and poly(ADP-ribosyl)ation develop normally but are susceptible to skin disease. Genes Dev 1995; 9:509-520.
38. Delaney CA, Wang LZ, Kyle S, White AW, Calvert AH, Curtin NJ, et al. Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. Clin Cancer Res 2000; 6:2860-2867.
39. Griffin RJ, Curtin NJ, Newell DR, Golding BT, Durkacz BW, Calvert AH. The role of inhibitors of poly(ADP-ribose) polymerase as resistance-modifying agents in cancer therapy. Biochimie 1995; 77:408-422.
40. Wood RD. Nucleotide excision repair in mammalian cells. J Biol Chem 1997; 272:23465-23468.
41. Williams SD, Birch R, Einhorn LH, Irwin L, Greco FA, Loehrer PJ. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 1987; 316:1435-1440.
42. Nakane H, Takeuchi S, Yuba S, Saijo M, Nakatsu Y, Murai H, et al. High incidence of ultraviolet-B- or chemical-carcinogen-induced skin tumors in mice lacking the xeroderma pigmentosum group A gene. Nature 1995; 377:165-168.
43. Koberle B, Masters JR, Hartley JA, Wood RD. Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumors. Curr Biol 1999; 9:273-276.
44. Li Q, Yu JJ, Mu C, Yunmbam MK, Slavsky D, Cross CL, et al. Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells. Anticancer Res 2000; 20:645-652.
45. Fink D, Aebi S, Howell SB. The role of DNA mismatch repair in drug resistance. Clin Cancer Res 1998; 4:1-6.
46. Quinn AG, Healy E, Rehman I, Sikkink S, Rees JL. Microsatellite instability in human non-melanoma and melanoma skin cancer. J Invest Dermatol 1995; 104:309-312.
47. Korabiowska M, Brinck U, Dengler H, Stachura J, Schauer A, Droese M. Analysis of the DNA mismatch repair proteins expression in malignant melanomas. Anticancer Res 2000; 20:4499-4505.
48. 6- methylguanine-DNA methyltransferase and N-methylpurine-DNA glycosylase in melanoma cells with acquired drug resistance. Int J Cancer 1999; 80:744-750.
49. Khanna KK, Jackson SP. DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet 2001; 27:247-254.
50. Korabiowska M, Tscherny M, Stachura J, Berger H, Cordon-Cardo C, Brinck U. Differential expression of DNA nonhomologous end-joining proteins Ku70 and Ku80 in melanoma progression. Mod Pathol 2002; 15:426-433.
51. Britten RA, Kuny S, Perdue S. Modification of non-conservative double-strand break (DSB) rejoining activity after the induction of cisplatin resistance in human tumor cells. Br J Cancer 1999; 79:843-849.
52. Grover R, Wilson GD. Bcl-2 expression in malignant melanoma and its prognostic significance. Eur J Surg Oncol 1996; 22:347-349.
53. Jansen B, Wacheck V, Heere-Ress E, Schlagbauer-Wadl H, Hoeller C, Lucas T, et al. Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet 2000; 356:1728-1733.
54. Bhoumik A, Ivanov V, Ronai Z. Activating transcription factor 2-derived peptides alter resistance of human tumor cell lines to ultraviolet irradiation and chemical treatment. Clin Cancer Res 2001; 7:331-342.
55. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001; 61:3071-3076.
56. An J, Sun YP, Adams J, Fisher M, Belldegrun A, Rettig MB. Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF) alpha, and TNF-related apoptosis-inducing ligand in prostate cancer. Clin Cancer Res 2003; 9:4537-4545.
57. Soengas MS, Capodieci P, Polsky D, Mora J, Esteller M, Opitz-Araya X, et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 2001; 409:207-211.
58. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999; 21:103-107.